Further elucidation of the genomics of endometrial cancer has the capability and promise of much needed understanding of causative factors of this disease and its hereditary predisposition, development of more effective therapeutics, and improved predictive indicators for use of chemotherapy and radiation therapy. Significant strides toward these goals have been accomplished by The Cancer Genome Atlas (TCGA) project, which has genomically characterized and distilled endometrial cancer into 4 major groups based on microsatellite instability (MSI), somatic copy number alterations (SCNAs), and somatic nucleotide substitutions. 1 These groups include: 1) an ultramutated group with a unique nucleotide change spectrum of increased cysteine-toalanine (C!A) transversion frequency; 2) a hypermutated group of cancers with MSI, most of which had mutL homolog 1 (MLH1) promoter methylation (MSI group); 3) a group of cancers with microsatellite stability (MSS) that had a relatively lower mutation frequency and low SCNAs; and 4) a serous-like group comprised of cancers with serous or mixed histology and a few high-grade endometrioid cancers, all of which harbored extensive SCNAs and a low mutation rate. 1 The ultramutated group included 17 tumors (7% of all tumors in the TCGA data set), all of which harbored mutations in the exonuclease domain of polymerase e (POLE), and was associated with improved progression-free survival (PFS) compared with all other groups, and the largest difference was observed when this ultramutated group was compared with the serous-like group.POLE and polymerase d (POLD1) belong to the B family of polymerases and are responsible for synthesizing the leading and lagging strands in eukaryotic DNA replication. 2 POLE and POLD1 form the major catalytic and proofreading units of Pole and Pold enzyme complexes, which ensure the high fidelity of DNA replication. Both POLE and POLD1 exhibit the greatest homology over their proofreading exonuclease domain (residues 268-471 and 304-517, respectively), which exhibit a high level of evolutionary conservation. It is estimated that their proofreading 3 0 to 5 0 exonuclease activity, which locates and replaces erroneous bases in the daughter strand, helps protect against genomic instability by improving the fidelity of DNA replication by at least 10-fold. 3 Several cancer genome sequencing efforts have consistently demonstrated that a small fraction of colorectal and endometrial cancers contain somatic mutations within the exonuclease domains of POLE (3% and 7% in the TCGA colorectal and uterine projects, respectively). 1,4 Contrary to POLE, very few somatic POLD1 exonuclease domain mutations (EDMs) have been detected in human cancers, whereas both germline POLD1 and POLE mutations have been reported in association with a high risk of multiple colorectal adenomas and carcinomas, whereas germline POLD1 mutations also predispose to endometrial cancers. 5 Somatic POLE EDMs in endometrial and colorectal cancers have demonstrated significant overlap; and codons 286 (a c...